Clinical Trial Background
Forest Hills Lab is a clinical-stage biopharmaceutical company bringing multiple assets into clinical trials. Our clinical development strategy accelerates drug development by focusing on:
– Precision medicine – targeting specific patient sub-groups who are most likely to benefit from the drug mechanisms under investigation
– Biomarkers – effectively using advanced biomarkers and imaging techniques to accurately identify and measure disease progression on a regular basis
– Combination approaches – leveraging our diverse pipeline to trial combinations of therapies that have already been de-risked individually
– Close collaboration – working closely with patient advocacy groups and research institutions to design trials that are both efficient and patient-friendly
Our first Phase II trial will be: “A Phase 2, Double-Blind, Multi-Center, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of FHL-301 in Adult Patients with Parkinson’s Disease”. Please Contact Us if you are a Parkinson’s disease patient or physician interested in participating.
FDA-Approved Study Design for FHL-301's
Phase II Clinical Trial
